[go: up one dir, main page]

MX2012003924A - Antagonistas peptidicos sinteticos de miostatina. - Google Patents

Antagonistas peptidicos sinteticos de miostatina.

Info

Publication number
MX2012003924A
MX2012003924A MX2012003924A MX2012003924A MX2012003924A MX 2012003924 A MX2012003924 A MX 2012003924A MX 2012003924 A MX2012003924 A MX 2012003924A MX 2012003924 A MX2012003924 A MX 2012003924A MX 2012003924 A MX2012003924 A MX 2012003924A
Authority
MX
Mexico
Prior art keywords
peptide antagonists
synthetic
myostatin peptide
myostatin
synthetic myostatin
Prior art date
Application number
MX2012003924A
Other languages
English (en)
Inventor
Robert Syndecombe Bower
Monica Senna Salerno De Moura
Gina Diane Nicholas
Mark Francis Thomas
Carole Judith Berry
Original Assignee
Covita Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covita Ltd filed Critical Covita Ltd
Publication of MX2012003924A publication Critical patent/MX2012003924A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)

Abstract

La presente invención se refiere a los nuevos antagonistas sintéticos de miostatina, que comprenden un péptido de miostatina maduro, sintético, en donde el péptido comprende al menos dos residuos de cisteína en las posiciones 281 y 282, que son forzados a enlazase y a formar un enlace disulfuro o una variante o fragmento funcional del mismo, y son útiles en el tratamiento de trastornos relacionados a la miostatina.
MX2012003924A 2009-10-01 2010-09-29 Antagonistas peptidicos sinteticos de miostatina. MX2012003924A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24782109P 2009-10-01 2009-10-01
PCT/NZ2010/000191 WO2011040823A1 (en) 2009-10-01 2010-09-29 Synthetic myostatin peptide antagonists

Publications (1)

Publication Number Publication Date
MX2012003924A true MX2012003924A (es) 2012-08-03

Family

ID=43826485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003924A MX2012003924A (es) 2009-10-01 2010-09-29 Antagonistas peptidicos sinteticos de miostatina.

Country Status (11)

Country Link
US (1) US20130065820A1 (es)
EP (1) EP2483300A4 (es)
JP (1) JP2013506660A (es)
KR (1) KR20120082909A (es)
CN (1) CN102741276A (es)
AU (1) AU2010301196A1 (es)
BR (1) BR112012007563A2 (es)
CA (1) CA2776529A1 (es)
MX (1) MX2012003924A (es)
NZ (1) NZ599604A (es)
WO (1) WO2011040823A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524057B1 (en) * 2010-01-15 2016-03-30 Rigel Pharmaceuticals, Inc. Screening assay employing dex and gdf8
HK1220367A1 (zh) * 2013-03-15 2017-05-05 Amgen Inc. 人类受试者中的肌抑素拮抗作用
JP6706617B2 (ja) 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
CN109071645A (zh) 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
WO2018030432A1 (ja) * 2016-08-10 2018-02-15 学校法人東京薬科大学 ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
US11155611B2 (en) * 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
US20210071183A1 (en) * 2018-02-26 2021-03-11 The Trustees Of Columbia University In The City Of New York Zinc associated treatment for and diagnosis of cachexia
WO2019179361A1 (zh) * 2018-03-21 2019-09-26 傅惠芳 改善括约肌闭锁不全的组合物及其医药组成物与用途
TWI649332B (zh) * 2018-03-21 2019-02-01 英屬安圭拉商維多利亞生物醫學控股股份有限公司 Composition for promoting local muscle growth, slowing or preventing local muscle atrophy and use thereof
EP3769779B1 (en) 2018-03-21 2023-12-27 Soulyoung Biotech Co., Ltd Composition for promoting local muscle growth or slowing down or preventing local muscle atrophy and use thereof
WO2021060880A1 (ko) * 2019-09-24 2021-04-01 마이오텍사이언스 주식회사 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
KR102836354B1 (ko) * 2021-11-25 2025-07-22 (주)네오크레마 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도
KR102840816B1 (ko) * 2021-11-25 2025-07-31 (주)네오크레마 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
WO2025159489A1 (ko) * 2024-01-22 2025-07-31 ㈜라트바이오 근육분화 촉진용 조성물 및 이의 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
MXPA01007366A (es) * 1999-01-21 2002-06-04 Metamorphix Inc Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
US8309068B2 (en) * 2006-08-03 2012-11-13 Myostin Therapeutics Pty Ltd. Isolated polypeptides and methods of improving muscle strength

Also Published As

Publication number Publication date
EP2483300A4 (en) 2013-02-27
BR112012007563A2 (pt) 2019-09-24
US20130065820A1 (en) 2013-03-14
KR20120082909A (ko) 2012-07-24
NZ599604A (en) 2014-07-25
JP2013506660A (ja) 2013-02-28
CN102741276A (zh) 2012-10-17
EP2483300A1 (en) 2012-08-08
CA2776529A1 (en) 2011-04-07
AU2010301196A1 (en) 2012-05-17
WO2011040823A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
MX2012003924A (es) Antagonistas peptidicos sinteticos de miostatina.
ZA201001054B (en) Peptide with reduced dimer formation
WO2009124971A3 (en) Novel compositions and their use
MY158438A (en) Antibodies against human angiopoietin 2
TN2014000134A1 (en) Therapeutic peptides
FR2959658B1 (fr) Bande de restauration de l'attache a un os d'un tissu mou tel qu'un tendon ou un ligament
MX339402B (es) Composiciones y metodos que comprenden variantes de serina proteasa.
IN2014DN09804A (es)
MX355181B (es) Anticuerpos humanos contra el factor tisular.
IL201685A0 (en) Cyclic peptide cxcr4 antagonists
MY181181A (en) Fgf21 derivatives and uses thereof
GB0710529D0 (en) Vaccine
HK1202800A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
FR2954225B1 (fr) Pneumatique munis de temoins d'usure sonores multiniveaux
NZ603939A (en) Conjugated blood coagulation factor viii
GB2492738A (en) Conjugated blood coagulation factor VIIA
WO2010106542A3 (en) USE OF NKp46 FOR PREVENTING DIABETES
BRPI0906027A2 (pt) "composições de poliamida, processos de fabricação de uma composição de poliamida e artigos"
TN2009000447A1 (en) An extented-release composition comprising a somatostatin derivative in microparticles
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
DE602006014250D1 (de) Flammhemmende kautschukzusammensetzung und kautschukprodukt daraus sowie beschichtungsmaterial für einen elektrischen draht
WO2007103584A3 (en) Polyamides for treating human papilloma virus
WO2014039074A3 (en) Therapeutic compositions and related methods
UA104714C2 (ru) Выделенный полинуклеотид brachyspira hyodysenteriae, кодирующий полипептид, и его применение
EP3211002A3 (en) Peptides derived from the ectodomain of nkp46

Legal Events

Date Code Title Description
FA Abandonment or withdrawal